# Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

> **NCT00006077** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 50 (—)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** NS2330
- **DRUG:** Levodopa and Domperidone

## Key facts

- **NCT ID:** NCT00006077
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 50 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006077, "Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00006077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*